文献速递炎症性肠病肝病消化内镜

炎症性肠病合并原发性硬化性胆管炎患儿症状与结肠镜检查所见不相关

Symptoms Do Not Correlate With Findings From Colonoscopy in Children With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-03-24

一项前瞻性研究纳入37例PSC-IBD患儿和50例单纯IBD对照,发现临床缓解的PSC-IBD患儿内镜和组织学活动风险显著高于对照(OR 5.9,95%CI 1.6-21.5),粪便钙卫蛋白与内镜评分相关,低于93 μg/g与黏膜愈合相关。

要点

  • 临床缓解的PSC-IBD患儿内镜活动风险高于无PSC的IBD患儿(OR 5.9,95%CI 1.6-21.5)。
  • PSC-IBD患儿PUCAI与UCEIS相关性(r=0.51)低于对照(r=0.82,P=0.01)。
  • 粪便钙卫蛋白识别PSC-IBD黏膜愈合的AUC为0.94,最佳切点93 μg/g(敏感度100%,特异度92%)。

核心结论

  • 基于PUCAI评分处于临床缓解的PSC-IBD患儿,其活动性内镜和组织学疾病风险显著高于无PSC的结肠炎患儿。
  • PSC-IBD患儿粪便钙卫蛋白水平与内镜所见相关,低于93 μg/g与黏膜愈合相关。

研究设计与样本

  • 前瞻性研究,纳入2016年2月1日至2017年3月31日在加拿大多伦多儿童医院接受结肠镜检查的年龄<18岁结肠IBD患儿,其中PSC-IBD 37例、单纯IBD对照50例。
  • 收集PUCAI评分和粪便钙卫蛋白,结肠镜采用Mayo内镜子评分和UCEIS评分,并进行组织学活动度分级。
  • 在临床缓解患者中比较内镜评分和活动性内镜疾病(UCEIS评分≥1)的比值比,并比较活动标志物间的相关性。
  • 采用受试者工作特征曲线分析评估粪便钙卫蛋白识别PSC-IBD患者黏膜愈合的能力,并对组织学活动进行类似分析。

主要发现

  • 临床缓解的PSC-IBD患儿内镜评分更高,活动性内镜疾病比值比高于对照(OR 5.9;95%CI 1.6-21.5)。
  • PUCAI与UCEIS的相关性在对照中为r=0.82,在PSC-IBD患儿中为r=0.51(P=0.01)。
  • 粪便钙卫蛋白与UCEIS在PSC-IBD患儿中r=0.84,在对照中r=0.82(P=0.80)。
  • 粪便钙卫蛋白识别PSC-IBD患儿黏膜愈合的AUC为0.94(最佳切点93 μg/g;敏感度100%,特异度92%)。
  • 临床缓解的PSC-IBD患儿组织学活动评分和活动性组织学疾病比值比也高于对照。

关键数值与推荐

  • 活动性内镜疾病基于UCEIS评分≥1定义。
  • 粪便钙卫蛋白识别黏膜愈合的AUC为0.94,最佳切点93 μg/g,敏感度100%,特异度92%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Approximately 75% of children with primary sclerosing cholangitis (PSC) also have inflammatory bowel disease (IBD). IBD in patients with PSC (PSC-IBD) often has a unique phenotype, including a mild clinical course, yet it is associated with an increased risk of colorectal cancer compared with colonic IBD without PSC. We investigated whether subclinical endoscopic and histologic inflammation could account for the increased risk of colorectal cancer in patients with PSC-IBD, and whether these patients have increased fecal levels of calprotectin, a marker of inflammation. METHODS: We performed a prospective study of children (age, <18 y) with colonic IBD with and without PSC who underwent colonoscopy from February 1, 2016, through March 31, 2017, at the Hospital for Sick Children in Toronto, Canada. We collected pediatric ulcerative colitis activity index (PUCAI) scores (to measure symptoms) and fecal levels of calprotectin from 37 children with PSC-IBD and 50 children with only IBD (controls; UC or IBD-unclassified). Colonoscopies were scored using the Mayo endoscopic subscore and the UC Endoscopic Index of Severity (UCEIS) scores, and histologic activity was graded. Among patients in clinical remission, endoscopic scores and the odds of active endoscopic disease (based on a UCEIS score ≥1) were compared between patients with and without PSC in univariate and multivariable analyses. Correlations between activity markers were compared between groups. The ability of fecal calprotectin to identify mucosal healing in patients with PSC-IBD was assessed using receiver operating characteristic curve analyses. Analogous analyses were performed for histologic activity. RESULTS: Patients with PSC-IBD in clinical remission had higher endoscopic scores and greater odds of active endoscopic disease than controls (odds ratio, 5.9; 95% CI, 1.6-21.5). There was a higher degree of correlation between PUCAI and UCEIS scores in controls (r = 0.82) than in patients with PSC-IBD (r = 0.51; P = .01). Fecal levels of calprotectin correlated with UCEIS in patients with PSC-IBD (r = 0.84) and controls (r = 0.82; P = .80). Fecal levels of calprotectin identified mucosal healing in patients with PSC-IBD with an area under the receiver operating characteristic curve of 0.94 (optimal cut-point, 93 μg/g; 100% sensitivity and 92% specificity). Histologic activity scores and the odds of active histologic disease were also greater in patients in clinical remission with PSC-IBD than controls. CONCLUSIONS: Children with PSC-IBD in clinical remission, based on PUCAI scores, have a significantly higher risk of active endoscopic and histologic disease than children with colitis without PSC. Fecal levels of calprotectin correlate with endoscopic findings in pediatric patients with PSC-IBD; levels below 93 μg/g are associated with mucosal healing.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Ricciuto A, Fish J, Carman N, et al. Symptoms Do Not Correlate With Findings From Colonoscopy in Children With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. Clin Gastroenterol Hepatol. 2018. PMID: 29378308. doi:10.1016/j.cgh.2018.01.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。